Department of Oncology, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, People's Republic of China.
Department of Oncology, The First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's Hospital, Hunan, People's Republic of China.
Sci Rep. 2023 Jun 8;13(1):9352. doi: 10.1038/s41598-023-36433-5.
This study evaluated the efficacy and safety of cisplatin and nedaplatin in three-week doublet agent concurrent chemoradiotherapy (CCRT) for patients with locally advanced cervical cancer (LACC). We retrospectively enrolled patients with stage IIB-IIIC2 cervical cancer who received doublet agent CCRT from January 2015 to December 2020. Clinical outcomes were analyzed using the Kaplan-Meier method and a Cox proportional hazards model. Propensity score (PS) matching analysis was used to compare cisplatin plus docetaxel group and nedaplatin plus docetaxel group. A total of 295 patients were included. The 5-year overall survival rate (OS) and progression free survival rate (PFS) were 82.5% and 80.4%, respectively. After PS matching, there were 83 patients each in the nedaplatin group and cisplatin group. There were no significant differences in objective response rates (97.6% and 98.8%, p = 0.212), 5-year OS rate (96.5 vs 69.8, p = 0.066), PFS rate (90.8 vs 72.4, p = 0.166), and toxicity between the two groups. Doublet agent concurrent chemoradiotherapy is feasible, safe, and shows high efficacy in LACC patients. Here, cisplatin group has a trend of better prognosis, suggesting that cisplatin is preferred and nedaplatin can be considered for replacement when cisplatin is intolerant.
本研究评估了顺铂和奈达铂在三周双药联合同期放化疗（CCRT）治疗局部晚期宫颈癌（LACC）患者中的疗效和安全性。我们回顾性纳入了 2015 年 1 月至 2020 年 12 月接受双药联合 CCRT 的 IIB-IIIC2 期宫颈癌患者。采用 Kaplan-Meier 法和 Cox 比例风险模型分析临床结局。采用倾向评分（PS）匹配分析比较顺铂加多西他赛组和奈达铂加多西他赛组。共纳入 295 例患者。5 年总生存率（OS）和无进展生存率（PFS）分别为 82.5%和 80.4%。PS 匹配后，奈达铂组和顺铂组各有 83 例。两组客观缓解率（97.6%和 98.8%，p=0.212）、5 年 OS 率（96.5% vs 69.8%，p=0.066）、PFS 率（90.8% vs 72.4%，p=0.166）和毒性无显著差异。双药联合同期放化疗在 LACC 患者中是可行的、安全的，且疗效较高。在此，顺铂组有更好预后的趋势，提示顺铂是首选，当不能耐受顺铂时可以考虑用奈达铂替代。
